PIV3

AcronymDefinition
PIV3Parainfluenza Virus Type 3
References in periodicals archive ?
Human metapneumovirus (hMPV) and parainfluenza type 3 (PIV3) vaccine (mRNA-1653): Topline data from a second planned interim analysis of an ongoing Phase 1 randomized, observer-blind, placebo-controlled and dose-ranging study in healthy adults showed that hMPV and PIV3 serum neutralizing antibody titers remained above baseline through seven months and the vaccine was generally well-tolerated.
Detection of parainfluenza 3-specific RNA from pericardial fluid or blood would offer direct evidence that PIV3 caused the effusion.
In the study, the FilmArray RP detected 50 positive viruses (ADV, 3; OC43, 7; HKU1, 1; NL63, 1; MPV, 2; HRV, 9; Flu A, 8; Flu B, 2; PIV3, 4; and RSV, 13, resp.).
Patients were diagnosed with PIV3 infection by viral nucleic acid amplification test (NAAT) done on nasopharyngeal swab and bronchoalveolar fluid lavage (BAL) samples.
It is a combination vaccine that consists of two distinct mRNA sequences encoding the fusion (F) proteins of hMPV and PIV3 formulated in Moderna's proprietary lipid nanoparticle technology.
Pathogens 0-3 m 4-6 m 7-12m 1-2y (n = 1110) (n =767) (n =1116) (n=2330) InfA 19 (1.7%) 12 (1.6%) 26 (2.5%) 109 (4.7%) InfB 3 (0.3%) 4 (0.6%) 10 (0.9%) 31 (1.3%) RSV 236 (21.3%) 176 (22.9%) 174 (15.6%) 270 (11.6%) ADV 3 (0.3%) 4 (0.5%) 13 (1.2%) 48 (2.1%) PIV1 4 (0.4%) 4 (0.5%) 7 (0.6%) 41 (1.8%) PIV2 0 (0%) 2 (0.3%) 2 (0.2%) 3 (0.1%) PIV3 27 (2.4%) 23 (3.0%) 60 (5.4%) 93 (4.0%) Pathogens 3-5y 6-10y 11-14y p-Value (n = 1805) (n =788) (n=115) InfA 84 (4.7%) 44 (5.6%) 8 (7.0%) <0.001 InfB 46 (2.5%) 46 (5.8%) 9 (7.8%) <0.001 RSV 88 (4.9%) 4 (0.5%) 1 (0.9%) <0.001 ADV 86 (4.8%) 23 (2.9%) 0 (0%) <0.001 PIV1 12 (0.7%) 1 (0.1%) 0 (0%) <0.001 PIV2 7 (0.4%) 0 (0%) 0 (0%) 0.182 PIV3 19 (1.1%) 2 (0.3%) 2 (1.7%) <0.001
Among patients with pH1N1, we found co-infections with PIV1 (n = 1), PIV3 (n = 2), PIV4 (n = 1), HCoV 229E (n = 1), HCoV OC43 (n = 1), respiratory syncytial virus (n = 7), and adenovirus (n = 5).
An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines.
rimantadine 100 mg 2x/d (DFA + in BAL) 3 Oseltamivir 150 mg 2x/d Aspergillus (PCR and GM result positive in BAL sample); Staphylococcus aureus; PIV3 4 Oseltamivir 2 mg/kg 2x/d None 5 Oseltamivir 150 mg 2x/d None 6 Oseltamivir 150 mg 2x/d None 7 Oseltamivir 75 mg 2x/d + Rhinovirus rimantadine 100 mg 2x/d (PCR result positive in NW sample) 8 Prophylaxis: oseltamivir 45 None mg 2x/d for 10 d, ended 3 d before influenza diagnosis Patient no.
These structures are similar to other known HNs, such as NDV and PIV3 dimers.
Twenty (71%) case-patients were co-infected with other respiratory viruses, most commonly RSV B (9/28, 32%), followed by HBoV (6/28, 21%), rhinovirus V and PIV3 (4 each of 28, 14%), human metapneumovirus (3/28, 11%), adenovirus and influenza A (2 each of 28, 7%), and 229E (1/28, 4%).
Antibody responses to bovine parainfluenza virus type 3 (PIV3) vaccination and human PIV3 infection in young infants.